New Delhi, July 22 -- The U.S. Food and Drug Administration's recent authorisation of modified-risk claims for certain non-combustible nicotine products is part of a broader international dialogue on strategies for tobacco and nicotine consumption.

For India, the pivotal question is whether the country's research institutions are willing to conduct an independent analysis of this emerging data, adapted to its own setting.

Findings are accumulating from nations that have adopted different oversight models. Sweden, the United Kingdom, Japan and Norway have documented drops in cigarette smoking alongside the uptake of non-combustible alternatives.

The United States permits modified-risk claims following FDA evaluation. None of these frame...